Table 6 Expression profiling of congestive heart failure (CHF).
Target tissue | Experimental design | Number of genes affected |
|---|---|---|
End-stage dilated cardiomyopathy (CM) [91] | Failing versus non-failing | 103 |
End-stage dilated CM [92] | Failing versus non-failing | 100 |
CM [93] | Dilated versus ischaemic myocardial tissu | 192 |
Human heart [94] | Four groups: i) left ventricle (LV); ii) LV from failing hearts affected by dilated CM); iii) LV from failing hearts affected by ischaemic CM; iv) right ventricl | 1,306 |
Human heart [98] | End-stage ischaemic and dilated CM | 12 (in CHF) 5 (exclusive to CHF) 2 (exclusive to non-CHF) |
Idiopathic dilated CM [101] | Pro-apoptotic genes | T umour necrosis factor- a signalling pathway |
Idiopathic dilated CM [102] | Left ventricular assist device (LVAD) suppor | 1,374 genes were reported as 'increased' and 1,629 as 'decreased' |
End-stage CHF [103] | LVAD support | 47 (pre- versus post-LVA D) |
End-stage CHF [104] | LVAD support | T wo distinct groups identifiable with present or absent LVAD |
End-stage CHF [105] | LVAD support | Focus on apelin |